Changes in albuminuria predict mortality and morbidity in patients with vascular disease - Wikidata - awgldk - TriplyDB

Changes in albuminuria predict mortality and morbidity in patients with vascular disease

Changes in albuminuria predict mortality and morbidity in patients with vascular disease

http://www.wikidata.org/entity/Q35108899

about

Interplay of vitamin D, erythropoiesis, and the renin-angiotensin system The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy Podocytes degrade endocytosed albumin primarily in lysosomes Predictive properties of plasma amino acid profile for cardiovascular disease in patients with type 2 diabetes.Impact of chronic kidney disease on the prevalence of cardiovascular disease in patients with type 2 diabetes in Spain: PERCEDIME2 study Association of high blood pressure with renal insufficiency: role of albuminuria, from NHANES, 1999-2006.Cumulative systolic BP and changes in urine albumin-to-creatinine ratios in nondiabetic participants of the multi-ethnic study of atherosclerosis Endocytosis of albumin by podocytes elicits an inflammatory response and induces apoptotic cell death.Predictors of progression in albuminuria in the general population: results from the PREVEND cohort.The clinical status and survival in elderly dialysis: example of the oldest region of France.Active vitamin D treatment for reduction of residual proteinuria: a systematic review.Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy.Urinary fetuin-A is a novel marker for diabetic nephropathy in type 2 diabetes identified by lectin microarray.Urinary immunoglobulin G to albumin ratio and N-Acetyl-Beta-D-Glucosaminidase as early predictors of therapeutic response in ANCA-associated glomerulonephritis.The predictive value of albuminuria for renal and nonrenal natural deaths over 14 years follow-up in a remote aboriginal community Risk Prediction for Early CKD in Type 2 Diabetes.Normal 25-Hydroxyvitamin D Levels Are Associated with Less Proteinuria and Attenuate Renal Failure Progression in Children with CKD.Urinary alpha-1 antitrypsin and CD59 glycoprotein predict albuminuria development in hypertensive patients under chronic renin-angiotensin system suppression Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre Predictive effects of urinary liver-type fatty acid-binding protein for deteriorating renal function and incidence of cardiovascular disease in type 2 diabetic patients without advanced nephropathy.Vitamin D analogues to target residual proteinuria: potential impact on cardiorenal outcomes.Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype.Doubling of serum creatinine and the risk of cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes mellitus: a cohort study.Global cardiovascular risk assessment in the management of primary hypertension: the role of the kidney Progression of glomerular filtration rate reduction determined in conscious Dahl salt-sensitive hypertensive rats.Association of a reduction in central obesity and phosphorus intake with changes in urinary albumin excretion: the PREMIER study A randomized trial of dietary sodium restriction in CKD Associations between proteinuria and cardiovascular risk factors among hypertensive patients in Andkhoy, Afghanistan.Individualization of antihypertensive drug treatment.Effect of remote ischaemic conditioning on contrast-induced nephropathy in patients undergoing elective coronary angiography (ERICCIN): rationale and study design of a randomised single-centre, double-blind placebo-controlled trial.Survival of chronic hemodialysis patients over 80 years of age Current challenges in the clinical management of hypertension.Microalbuminuria as surrogate endpoint in therapeutic trials.Cardiovascular disease in chronic kidney disease: untying the Gordian knot.Update on the ROADMAP clinical trial report: olmesartan for the prevention or delay of microalbuminuria development in type 2 diabetes.Medical management and strategies to prevent coronary artery disease in patients with type 2 diabetes mellitus.Renal sympathetic denervation: applications in hypertension and beyond.Chronic kidney disease induced dysfunction of high density lipoprotein.Assessment of target organ damage in the evaluation and follow-up of hypertensive patients: where do we stand?Renal denervation--implications for chronic kidney disease.

P2860

Q26822500-2BDE0CA7-3A1D-443F-B88B-0382FBD80A3E Q28237978-4A4402A5-34EF-41C4-BB7F-A6D9CE5A1FF2 Q33748757-DE48149E-565D-4C51-B55E-96F6C5397DAB Q33817483-681ADBB9-6DE8-4F06-A3FF-914283981FA0 Q34272651-1B570626-B288-43AE-BCF4-13B7D4B44CB4 Q34339595-3C860A82-0F99-4633-9B7F-30362379D0DD Q34455151-53CA9FA7-6F74-40DA-ADEB-A8BD99FCE612 Q34575711-0291EF47-6883-4A61-8CF6-AB4108E4E2D1 Q34749180-B1438339-A9F7-4601-8845-1BE6941FDB81 Q34783006-AAECB72C-E57E-40FF-82D8-1D7B8C7D9737 Q34912750-07FBBAF4-D85A-4B38-B126-B8F1A3C861EF Q34926825-73C1C588-AA54-4FDF-B1AD-0181B8A568D1 Q35021685-F15803AA-F70B-401D-9655-1059EE28ED7F Q35069739-05E69B0C-30D4-4D47-BD80-6364DE7E5632 Q35452988-51EFB2BD-5F92-42DE-91C6-2AFE851B6EBB Q35691583-E8EB993B-4937-4792-85E7-A024D68E282F Q36417881-566C0BB7-12ED-4B53-A8F5-273EC5267E80 Q36469066-242DE0FC-FCAB-4A1C-A5E6-7E99360B768F Q36670632-5F620C9D-FE75-4D01-881A-07843458F1EB Q36782780-DA90FDE0-FA8A-4226-B589-B133029D6A20 Q36801566-2C76C98F-B968-45DD-B822-AFEBFE5118FD Q36851491-591848C6-FFFD-4B9E-AE1E-E08290729AF5 Q37012488-93DAD9FE-6583-4FCC-92D5-E220DE54968C Q37100961-E5486790-77C7-488C-B195-F6C70734724D Q37251235-24D3F776-A5DF-4ECE-98F5-4A34398BCD0E Q37258125-7BE5FDC4-4B76-4802-A910-A5B706C560F7 Q37340221-FE89BE00-4AC1-477A-B5CC-54A5118EA1B5 Q37507414-75CA8B87-0590-46DC-86F2-428E29040BE1 Q37577140-704502C9-F5A6-4573-B55E-3622175D9B6E Q37608257-39657BC4-A1F9-4B2A-AD68-B0BE50596B31 Q37721841-80B3C799-4C76-4436-A9BE-BB172C21ABB4 Q37949514-31045480-69F7-4E2E-B78C-9351488B4527 Q38008566-BEDC0434-D1A4-4138-9C29-16AFC83E07CB Q38025185-61F1DBF7-6DB0-4F67-B46F-829FB39FF986 Q38055501-1594CF11-5BAC-43B6-A443-FBFB2BE636EC Q38079914-3A38D2EF-4967-4892-8FF7-A04E44262B60 Q38115114-1405BDBE-CEF2-4C1F-89AE-E8259C9F3D57 Q38135683-910439BD-5AC1-47C9-A7C3-1885AD45B816 Q38148620-2B9D4A77-FA19-44F7-AE53-6743013081FE Q38204682-905C9D36-3449-430C-8E45-5182BEB80997

P2860

Changes in albuminuria predict mortality and morbidity in patients with vascular disease

http://www.wikidata.org/entity/Q35108899

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Changes in albuminuria predict mortality and morbidity in patients with vascular disease

@ast

Changes in albuminuria predict mortality and morbidity in patients with vascular disease

@en

type

label

Changes in albuminuria predict mortality and morbidity in patients with vascular disease

@ast

Changes in albuminuria predict mortality and morbidity in patients with vascular disease

@en

prefLabel

Changes in albuminuria predict mortality and morbidity in patients with vascular disease

@ast

Changes in albuminuria predict mortality and morbidity in patients with vascular disease

@en

P1433

Q35108899-0B3C7F38-9BDE-4F5B-AC40-B25F403D1746

P1476

Q35108899-909AA53B-9F34-4108-971C-894C5DE999AB

P2093

Q35108899-076C3111-A942-4284-B411-5C75E487ACA1

Q35108899-255C782C-6895-4362-9300-3B1079E0A652

Q35108899-61A181FA-D839-4372-A9C4-7BD9AE2D38AA

Q35108899-C6BBB49B-8DD8-42F9-9F25-284E21DD5194

Q35108899-F64225DB-4CD1-4384-8039-30852D5641AB

Q35108899-F8E5C4AF-C498-42D0-87B0-4B09CE6FCCFE

Q35108899-FE9018A8-A1AA-4E09-B3D7-CC0B95569498

Q35108899-FFEAA9CD-EE99-44C7-AB79-4AEE998746CA

P2860

Q35108899-118D1F9A-0DDB-40D6-B883-A4A7174F6574

Q35108899-140B0C4C-1250-4681-9ECD-DB343D1913B9

Q35108899-1618EB15-5048-4C63-BD6D-A46DC097162E

Q35108899-2BE78492-967D-4CC6-9DD0-5CC9DEB037FF

Q35108899-2DC44E40-B362-4912-9D90-6DBF37F270FF

Q35108899-3CD6E405-2DBC-47B9-A61D-EDC1F36C94B9

Q35108899-65324E04-C621-4671-B025-EAC30154BB47

Q35108899-67FC08B8-0720-42F3-9AA2-F78370205D08

Q35108899-680AE5BA-D356-41F9-8554-21507FF8BA50

Q35108899-6C4A6F24-4A3F-4CF4-8172-293D1E4C9326

P304

Q35108899-9F86E052-F528-47C7-B83E-94A695DEB81F

P31

Q35108899-F3EC701D-5774-457C-8349-F1CE9DBAF41E

P356

Q35108899-37E8D7BC-6EB7-44C0-A5E8-0219F2278BF9

P433

Q35108899-599F5CAE-3C24-4283-9ABB-560DB24E2041

P478

Q35108899-BDEC31BB-A85A-41C2-8831-FC7B6F9A76C9

P50

Q35108899-34A2DBE1-6732-4D28-961E-DC172B2579CC

Q35108899-F4393440-ACFF-43EC-B534-6161F77684EB

P577

Q35108899-1576E0AF-55F0-4FB4-9227-2E10AC6905B5

P698

Q35108899-E580833D-C4AA-445D-A712-9DBED13B524A

P932

Q35108899-20E59CC6-D252-4D2E-9BF4-03C0033D8B28

P356

P1433

Journal of the American Society of Nephrology

P1476

Changes in albuminuria predict mortality and morbidity in patients with vascular disease

@en

P2093

Helmut Schumacher

http://www.w3.org/2001/XMLSchema#string

Johannes F E Mann

http://www.w3.org/2001/XMLSchema#string

Matthew McQueen

http://www.w3.org/2001/XMLSchema#string

Michael A Weber

http://www.w3.org/2001/XMLSchema#string

ONTARGET Investigators

http://www.w3.org/2001/XMLSchema#string

Peggy Gao

http://www.w3.org/2001/XMLSchema#string

Roland E Schmieder

http://www.w3.org/2001/XMLSchema#string

Teo Koon

http://www.w3.org/2001/XMLSchema#string

P2860

Association of heart rate with microalbuminuria in cardiovascular risk patients: data from I-SEARCH.

Telmisartan, ramipril, or both in patients at high risk for vascular events.

The relationship between proteinuria and coronary risk: a systematic review and meta-analysis

Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III.

Assessing kidney function--measured and estimated glomerular filtration rate.

Time to abandon microalbuminuria?

Predictive power of sequential measures of albuminuria for progression to ESRD or death in Pima Indians with type 2 diabetes.

Low-grade albuminuria and cardiovascular risk : what is the evidence?

First morning voids are more reliable than spot urine samples to assess microalbuminuria.

Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes

P304

1353-1364

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1681/ASN.2010091001

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

Giuseppe Mancia

P577

2011-06-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21719791

http://www.w3.org/2001/XMLSchema#string

P932

3137583

http://www.w3.org/2001/XMLSchema#string